Related Experiment Video
Updated: Jul 22, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Erlotinib in non-small cell lung cancer: a review
Fiona H Blackhall1, Shazza Rehman, Nicholas Thatcher
1Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. Fiona.Blackhall@christie-tr.nwest.nhs.uk
Abstract:
Erlotinib (Tarceva, OSI-774; Pfizer, Inc.) is an orally-active, targeted inhibitor of the epidermal growth factor receptor (EGFR/HER1), which is part of a key regulatory pathway in cancer. Patients with advanced, incurable non-small cell lung cancer (NSCLC) may derive a clinical benefit from first- and second-line chemotherapy, but third-line treatment with available cytotoxic agents is not effective. Remarkably, EGFR/HER1 antagonists have demonstrated activity as second- and even third-line treatment for this disease. Erlotinib is the first of this novel class of drug to demonstrate a statistically significant and clinically relevant difference in overall survival, progression free survival and time to disease related symptoms (cough, pain, shortness of breath) compared with treatment with best supportive care in patients who have failed standard first- or second-line chemotherapy. This paper reviews the pharmacology, preclinical and clinical data to support the use of erlotinib in NSCLC.
Insights
Erlotinib, an epidermal growth factor receptor inhibitor, offers significant survival benefits for advanced non-small cell lung cancer patients who have not responded to chemotherapy. This targeted therapy improves progression-free survival and reduces disease-related symptoms.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Non-small cell lung cancer (NSCLC) has limited treatment options beyond first- and second-line chemotherapy.
- Epidermal growth factor receptor (EGFR/HER1) signaling pathways are crucial in cancer development.
- Third-line treatment for advanced NSCLC with cytotoxic agents shows limited efficacy.
Purpose of the Study:
- To review the pharmacology, preclinical, and clinical data supporting erlotinib's use in NSCLC.
- To evaluate erlotinib as a targeted therapy for advanced NSCLC.
- To assess the efficacy of erlotinib in patients who have failed standard chemotherapy.
Main Methods:
- Review of pharmacological properties of erlotinib.
- Analysis of preclinical data on EGFR/HER1 inhibition.
- Evaluation of clinical trial data in NSCLC patients.
Main Results:
- Erlotinib demonstrated statistically significant improvements in overall survival and progression-free survival.
- Erlotinib showed a significant delay in the time to disease-related symptoms (cough, pain, shortness of breath).
- Erlotinib provided clinical benefit as a third-line treatment option for advanced NSCLC.
Conclusions:
- Erlotinib is a novel, orally-active targeted inhibitor of EGFR/HER1.
- Erlotinib represents a significant advancement in the treatment of advanced NSCLC.
- Erlotinib offers a clinically relevant benefit for patients with refractory NSCLC.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
07:59Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
